Dr. Muss on Assessing Treatment Response in Patients With Metastatic Breast Cancer

Hyman B. Muss, MD
Published: Monday, Jun 27, 2016


Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses assessing treatment response in patients with metastatic breast cancer.

It can be challenging to choose between the various follow-up options for patients with metastatic breast cancer, Muss explains, from physical exams to imaging tools. Since many patients will have short-term responses to treatment, they do not need comprehensive and expensive follow-up tests, Muss explains.

Treatment regimens for metastatic breast cancer should be designed to control disease while maintaining a good quality of life; however, quality of life can become a lower priority in clinical practice, he says.

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses assessing treatment response in patients with metastatic breast cancer.

It can be challenging to choose between the various follow-up options for patients with metastatic breast cancer, Muss explains, from physical exams to imaging tools. Since many patients will have short-term responses to treatment, they do not need comprehensive and expensive follow-up tests, Muss explains.

Treatment regimens for metastatic breast cancer should be designed to control disease while maintaining a good quality of life; however, quality of life can become a lower priority in clinical practice, he says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x